Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT04430842

NCT04430842
Completed Phase 1 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are 18 years old or older
  • Your bone marrow, kidneys, and liver are functioning well enough (as determined by blood tests)
  • Any side effects from previous cancer treatments have mostly cleared up or are mild
  • You have been diagnosed with an advanced or spreading solid tumor (confirmed by lab testing) in one of these areas: bladder, brain, breast, cervix, bile ducts, colon/rectum, esophagus, stomach, head and neck, kidney, liver, lung, skin (melanoma), ovaries, pancreas, pleural lining, prostate, soft tissue/bone (sarcoma), tongue, thymus, or urinary tract — and standard treatments have not worked, you cannot tolerate them, or no curative treatment exists
  • You have at least one measurable tumor that has not previously been treated with radiation
  • You are generally able to carry out light daily activities (your overall health and activity level fall within an acceptable range, as assessed by your doctor)

Who may not be able to join:

  • Your cancer is mainly located in the brainstem or spinal cord, or you have active, uncontrolled cancer that has spread to the brain or its surrounding tissue
  • Your cancer has spread widely to internal organs and is considered life-threatening in the short term (for example, large uncontrolled fluid buildups or more than half of your liver affected by cancer)
  • You have had another active cancer within the past 3 years (with some exceptions for certain minor skin cancers)
  • You have had major surgery within the past 4 weeks
  • You have had radiation therapy within the past 4 weeks (except limited radiation to bone lesions)
  • You have received systemic cancer treatment (such as chemotherapy) within the past 4 weeks
  • You have had bleeding from veins in your esophagus or stomach within the past 2 months
  • You have fluid build-up in your abdomen that cannot be managed
  • Your heart electrical activity (ECG) shows significant abnormalities that could affect your safety in the trial
  • You are currently on blood-thinning medication (certain types may be allowed — confirm with trial site)
  • In the past 6 months you have had a heart attack, serious heart rhythm problems, unstable chest pain, heart bypass surgery, a stroke or mini-stroke, significant heart failure, or a serious blood clot in the lungs or elsewhere
  • You have high blood pressure that remains above 150/90 mmHg even with medication, or requires more than two medications to control

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Quadriga Biosciences, Inc.
Registry
clinicaltrials_gov
Start date
20 July 2020
Est. completion
21 September 2022

Where this trial is recruiting

🇦🇺 Australia

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Determination of maximum tolerated dose (MTD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov